Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that Bruce D. Cheson, M.D., Professor of Medicine, Head of Hematology and Director of Hematology Research at Georgetown University Hospital’s Lombardi Comprehensive Cancer Center, has joined its Medical Imaging Scientific Advisor Team. Perceptive combines the expertise of its global medical imaging team with the specialized therapeutic area expertise of these advisors to help clients make better, more informed decisions regarding the best use of medical imaging and associated clinical data in their development programs.
Dr. Cheson, who currently chairs the Lymphoma Committee of the Cancer and Leukemia Group B and AJCC Subcommittee on Lymphoma, is an author on the widely accepted assessment criteria for Non-Hodgkin’s Lymphoma (NHL) (1999 and 2007 IWG-NHL) and Chronic Lymphocytic Leukemia (CLL) (1996 NCI-WG and 2008 IWCLL), which are standardized guidelines for assessing response to treatment. The guidelines provide clinicians worldwide with consistent criteria to compare and interpret clinical trials in these treatment indications and facilitate the development of new therapies.
“Perceptive is extremely pleased to have Dr. Cheson join our team of medical imaging scientific advisors. We believe that Dr. Cheson’s in-depth, specialized expertise and focus on development and evaluation of new therapeutic approaches for hematologic malignancies will be of value to our clients in their imaging-based oncology and hematology clinical trials,” said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics.
“With lymphoma being the most common blood cancer and the third most common childhood cancer, an overall goal is to improve therapies for patients with lymphoma. I am pleased to be affiliated with Perceptive Informatics, which is a leader in the successful management of medical imaging in trials, and advancing medical imaging as an endpoint, or biomarker, in determining safety and efficacy of important new hematologic treatments,” said Dr. Cheson. “I look forward to contributing my knowledge to Perceptive’s clients in the application of the assessment criteria for NHL and CLL.”
Dr. Cheson will co-present on the upcoming Perceptive webinar entitled “Understanding the Assessment Criteria for Lymphoma and Chronic Lymphocytic Leukemia (CLL): History, Enhancements and Clarifications,” to be held on January 28, 2010 in two sessions at 10:00 a.m. and 2:00 p.m. EST. Dr. Cheson will be joined by another scientific advisor to Perceptive Informatics: Matthew A. Barish, M.D., Assistant Clinical Professor, Co-Director of Body Imaging and Director of MRI at Stony Brook University Medical Center. While the assessment criteria are well accepted, the wide range of interpretations and applications continues to be a challenge in clinical trials where consistent assessment across sites is critical to the validity of the data. This webinar will offer clarifications for applying the revised criteria in clinical trials, with a particular emphasis on protocols and independent review analysis. For registration and more information about this webinar visit www.perceptive.com/News/Webinars/webinar.html?id=81.
The Medical Imaging Group of Perceptive Informatics offers a full range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, neurology, rheumatology, cardiology, and endocrinology. Perceptive’s medical imaging technologies are fully validated and in compliance with regulatory guidelines.
About Perceptive Infor